Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
Strokes are affecting approximately 1.8 million people annually
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
We now rank 3rd in pharmaceutical production by volume and 14th by value
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
CSPC will receive an upfront payment of $100 million from AstraZeneca
Subscribe To Our Newsletter & Stay Updated
